In his presentation, Professor Dirk Müller-Wieland from Asklepios Clinic St. Georg in Hamburg, Germany, shared evidence that the TANTALUS device significantly reduced HbA1c in diabetic treatment recipients. TANTALUS users also experienced notably reduced blood pressure, improved lipid profiles, and reductions in their body mass indices.
According to another presenter, Professor Bernhard Ludvik from the Medical University of Vienna, “TANTALUS is well tolerated by patients and maintains its beneficial effect on blood glucose levels and weight for periods of at least 2 years."
The most recent results were a graduation from outcomes presented in 2009, showing that moderately obese implantees in a 6-month trial achieved a 1% HbA1c reduction by the end of the study.1 The current results suggest that patients using the TANTALUS device can maintain that benefit for at least 2 years.
The TANTALUS system is currently approved for marketing in the European Union. The company has not yet indicated its intentions to seek approval for the device in the United States. However, TANTALUS’s manufacturer, MetaCure, Inc., is currently sponsoring clinical studies to further evaluate the implantable device’s potential in moderately obese people with diabetes. The largest study, just initiated, seeks to enroll 400 moderately obese diabetic patients in European trial sites.2
TANTALUS is intended for moderately obese people with diabetes who do not meet the guidelines for gastric bypass surgery. It is not likely to compete against gastric bypass surgery’s ability to help severely obese patients shed dozens of pounds and dramatically lower body mass index and blood glucose. However, it may offer a significant weapon for moderately obese diabetics.